Effect of various natural products on growth of bladder cancer cells: Two promising mushroom extracts

Alternative Medicine Review

Volumn 12, Issue 1, 2007, Pages 63-68

  Konno, Sensuke ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; MUSHROOM EXTRACT; MUSHROOM EXTRACT GD FRACTION; MUSHROOM EXTRACT PL FRACTION; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; HUMAN CELL; MUSHROOM;

AGARICALES; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; COMPLEMENTARY THERAPIES; FUNGI; GRIFOLA; HUMANS; URINARY BLADDER NEOPLASMS; VITAMINS;

EID: 34247638357     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Pow-Sang JM, Seigne JD. Contemporary management of superficial bladder cancer. Cancer Control 2000;7:335-339.
2. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 1992;6:1-30.
3. Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982;127:250-252.
4. Witjes JA, Mulders PF, Debruyne FM. Intravesical therapy in superficial bladder cancer. Urology 1994;43:2-5.
5. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992;19:573-580.
6. O'Donnell MA, De Wolf WC. Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am 1995;4:189-202.
7. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999;353:1689-1694.
8. Kurth KH, Bouffioux C, Sylvester R, et al. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol 2000;37:1-9.
9. Amling CL. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 2001;25:219-278.
10. Deresiewicz RL, Stone RM, Aster JC. Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin. J Urol 1990;144:1331-1333.
11. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
12. Mizuno T, Zhuang C. Maitake, Grifola frondosa: pharmacological effects. Food Rev Int 1995;11:135-149.
13. Hishida I, Nanba H, Kuroda H. Antitumor activity exhibited by orally administered extract from fruit body of Grifola frondosa (maitake). Chem Pharm Bull (Tokyo) 1988;36:1819-1827.
14. Adachi K, Nanba H, Kuroda H. Potentiation of host-mediated antitumor activity in mice by beta-glucan obtained from Grifola frondosa (maitake). Chem Pharm Bull (Tokyo) 1987;35:262-270.
15. Morishige F. The role of vitamin C in tumor therapy (human). In: Meyskens FI Jr, Parasad KN, eds. Vitamins and Cancer: Human Cancer Prevention by Vitamins and Micronutrients. Clifton, NJ: Humana Press; 1986:399-427.
16. Lamm DL, Riggs DR, Shriver JS, et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994;151:21-26.
17. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 2005;102:13604-13609.